Soluble telmisartan bearing poly (ethylene glycol) conjugated chitosan nanoparticles augmented drug delivery, cytotoxicity, apoptosis and cellular uptake in human cervical cancer cells

被引:16
作者
Sharma, Anjali [1 ]
Jyoti, Kiran [1 ]
Bansal, Vikas [1 ]
Jain, Upendra Kumar [1 ]
Bhushan, Bharat [2 ]
Madan, Jitender [1 ]
机构
[1] Chandigarh Coll Pharm, Dept Pharmaceut, Mohali 140307, Panjab, India
[2] Hindu Coll Pharm, Dept Pharmaceut Chem, Sonepat, Haryana, India
来源
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS | 2017年 / 72卷
关键词
Cervical cancer; Intravaginal route; Soluble telmisartan; Poly (ethylene-glycol) grafted chitosan nano-particles; Cytotoxicity; Apoptosis and cellular uptake; ACTIVATED RECEPTOR-GAMMA; IN-VITRO; RELEASE; PARTICLES; TARGET; MUCUS;
D O I
10.1016/j.msec.2016.11.048
中图分类号
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号
0805 ; 080501 ; 080502 ;
摘要
Soluble telmisartan and telmisartan were loaded in to poly (ethylene-glycol) grafted chitosan nanoparticles (S-TEL-PEG-CNPs and TEL-PEG-CNPs) for targeting cervical cancer through non-invasive, intravaginal route. The mean particle size of S-TEL-PEG-CNPs was measured to be 23.4 +/- 5.9-nm significantly (P < 0.05) higher than 16.2 +/- 3.2-nm of TEL-PEG-CNPs. In contrast, the zeta-potential (-21.5 +/- 4.6-mV) of S-TEL-PEG-CNPs was insignificantly (P > 0.05) different from-23.8 +/- 3.7-mV of TEL-PEG-CNPs. In addition, S-TEL-PEG-CNPs exhibited higher percent mucoadhesiveness (40.2%) in comparison (P < 0.05) to 31.4% of TEL-PEG-CNPs, although it was lower than CNPs (100%). S-TEL-PEG-CNPs displayed significantly (P < 0.01) higher dissolution of drug, 92.5% in comparison to 31.6% from TEL-PEG-CNPs up to 24 h. Furthermore, S-TEL-PEG-CNPs exhibited superior cytotoxicity, apoptosis and cellular uptake, analyzed in human cervical cancer, HeLa cells. The IC50 of S-TEL-PEG-CNPs was measured to be 223-mu m significantly (P < 0.05) lower than 40.1-mu M of TEL-PEG-CNPs. S-TEL-PEG-CNPs induced higher extent of apoptosis (P< 0.05) in HeLa cells as compared to TEL-PEG-CNPs, owing to higher diffusion of drug across biological membrane. Finally, quantitative and qualitative cellular uptake assay Confirmed the greater endocytosis of S-TEL-PEG-CNPs in HeLa cells due to diffusion, amorphization, hydrophilicity, and submicron size particularly, below 100 nm. In conclusion, S-TEL-PEG-CNPs warrant further in vivo tumour regression study to scale up the technology for clinical translation. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:69 / 76
页数:8
相关论文
共 44 条
  • [1] Why consider vaginal drug administration?
    Alexander, NJ
    Baker, E
    Kaptein, M
    Karck, U
    Miller, L
    Zampaglione, E
    [J]. FERTILITY AND STERILITY, 2004, 82 (01) : 1 - 12
  • [2] Disulfiram-loaded immediate and extended release vaginal tablets for the localised treatment of cervical cancer
    Baffoe, Clara S.
    Nhi Nguyen
    Boyd, Peter
    Wang, Weiguang
    Morris, Mark
    McConville, Christopher
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2015, 67 (02) : 189 - 198
  • [3] Methotrexate-Loaded PEGylated Chitosan Nanoparticles: Synthesis, Characterization, and in Vitro and in Vivo Antitumoral Activity
    Chen, Juan
    Huang, Liuqing
    Lai, Huixian
    Lu, Chenghao
    Fang, Ming
    Zhang, Qiqing
    Luo, Xuetao
    [J]. MOLECULAR PHARMACEUTICS, 2014, 11 (07) : 2213 - 2223
  • [4] Barrier properties of mucus
    Cone, Richard A.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (02) : 75 - 85
  • [5] Vaginal mucoadhesive drug delivery systems
    de Araujo Pereira, Raphaela Regina
    Bruschi, Marcos Luciano
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2012, 38 (06) : 643 - 652
  • [6] AMPICILLIN-LOADED LIPOSOMES AND NANOPARTICLES - COMPARISON OF DRUG LOADING, DRUG RELEASE AND INVITRO ANTIMICROBIAL ACTIVITY
    FATTAL, E
    ROJAS, J
    ROBLOTTREUPEL, L
    ANDREMONT, A
    COUVREUR, P
    [J]. JOURNAL OF MICROENCAPSULATION, 1991, 8 (01) : 29 - 36
  • [7] Freimoser FM, 1999, APPL ENVIRON MICROB, V65, P3727
  • [8] Telmisartan is a potent target for prevention and treatment in human prostate cancer
    Funao, Kiyoaki
    Matsuyama, Masahide
    Kawahito, Yutaka
    Sano, Hajime
    Chargui, Jamel
    Touraine, Jean-Louis
    Nakatani, Tatsuya
    Yoshimura, Rikio
    [J]. ONCOLOGY REPORTS, 2008, 20 (02) : 295 - 300
  • [9] QUANTITATION OF THE RELEASE OF DOXORUBICIN FROM COLLOIDAL DOSAGE FORMS USING DYNAMIC DIALYSIS
    GUPTA, PK
    HUNG, CT
    PERRIER, DG
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (02) : 141 - 145
  • [10] The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle
    Holmgren, SC
    Patterson, NA
    Ozbun, MA
    Lambert, PF
    [J]. JOURNAL OF VIROLOGY, 2005, 79 (07) : 3938 - 3948